Finotonlimab (PD-1 inhibitor) plus bevacizumab (bevacizumab biosimilar) as first-tier therapy for late-stage hepatocellular carcinoma: a randomized phase 2/3 trialChuanhua Zhao, Chuan Jin, Yanqiao Zhang et al.|Signal Transduction and Targeted Therapy|2025Cited by 20
Successful treatment with tislelizumab plus chemotherapy for SMARCA4-deficient undifferentiated tumor: a case reportWen Dong, Zemin Xiao, Tao Wu et al.|Frontiers in Immunology|2024Cited by 7